The New York Stock Exchange hereby notifies the SEC
 of its intention to remove the entire class of the
stated securities from listing and registration on
the Exchange at the opening of business on April 19,
2010, pursuant to the provisions of Rule 12d2-2 (a).

[ X ] 17 CFR 240.12d2-2 (a) (4) That all rights
pertaining to the entire class of this security were
extinguished on February 18, 2010.

Pursuant to the terms of the Rights of Allergan Inc,
the Rights expired and became null and void
on February 18, 2010.

The Exchange also notifies the Securities and Exchange
Commission that as a result of the above indicated
conditions this security was suspended from trading
on February 19, 2010.